Adamis Pharmaceuticals
2658 Del Mar Heights Road
Suite 555
Del Mar
California
92014
United States
185 articles about Adamis Pharmaceuticals
-
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™Drug overdoses are the leading cause of death for those under age 50
12/1/2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.
-
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
11/23/2021
Adamis Pharmaceuticals Corporation announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the company that based on the company’s filing of its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021, June 30, 2021 and September 30, 2021.
-
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
11/19/2021
Adamis Pharmaceuticals Corporation today announced that it will host an investor conference call on Monday, November 22, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first nine months of 2021, as well as provide a business update.
-
Zimhi is indicated for use in both adults and children in the event of an emergency. It is to be given right away and does not take the place of emergency care.
-
Adamis Receives FDA Approval for ZIMHINew High-Dose Naloxone Product for the Treatment of Opioid Overdose
10/18/2021
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.
-
ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS
10/12/2021
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) to Supernus Pharmaceuticals, Inc.
-
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
10/4/2021
Adamis Pharmaceuticals Corporation announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors.
-
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
9/2/2021
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
-
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
8/24/2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer reviewed journal, Clinical Immunology, entitled “Tempol, a novel antioxidant, inhibits both activated T cell and APC (Antigen Presenting Cell) derived cytokines in-vitro from COVID-19 patients."
-
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
8/24/2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately.
-
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19
8/19/2021
Adamis Pharmaceuticals Corporation ) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19
-
Adamis Announces Agreement to Sell Portion of US Compounding Business
8/4/2021
Adamis Pharmaceuticals Corporation announced that it has entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc., related to USC’s human compounding pharmaceutical business and customers, in exchange for total gross consideration estimated to be up to $15 million before transaction fees and expenses.
-
Adamis Announces Results of 2021 Annual Meeting of Stockholders
7/19/2021
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors
-
Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
7/13/2021
Adamis Pharmaceuticals Corporation urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors at the upcoming Annual Meeting of Stockholders on July 16, 2021.
-
Adamis Sends Letter to Stockholders to Address Jerald A. Hammann’s Costly, Distracting and Misguided Campaign
7/1/2021
Adamis Pharmaceuticals Corporation today issued the below letter to stockholders.
-
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
6/28/2021
The Board of Directors appreciates your continued investment in Adamis Pharmaceuticals Corporation. Ahead of our Annual Meeting of Stockholders on July 16th, we want to once again urge you to vote to re-elect all five members of the Board.
-
Adamis has sent a letter to stockholders urging them to re-elect all the five board members as part of a strategic move to continue and maintain its current growth initiatives.
-
Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders
6/14/2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission.
-
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19
6/11/2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol.
-
Adamis Provides Update on ZIMHI™FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021
6/9/2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose